Jitongning tablet(High-dose )
DrugJitongning tablet,3tablets,bid,treat 12 weeks
Other names: Jitongning tablet,3tablets
NCT Number: NCT03932019
This study is to investigate the efficacy and safety of Jitongning Tablet in improving joint function and pain symptoms in active axial spondyloarthritis (SpA) patients and to explore the optimal dosage.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, Anhui, China
Jitongning Tablet is a kind of traditional Chinese medicine(TCM), consists of Cortex Eucommiae, Duhuo(Radix Angelicae Pubescentis), Zhichuanwu(Radix Aconiti) , Rhizoma Corydalis, Radix Paeoniae Rubra, Radix Puerariae and Radix Glycyrrhizae. This study is being conducted to evaluate the efficacy and safety of Jitongning Tablet in patients with active axial spondyloarthritis (SpA) (Syndrome Of Kidney Yang Deficiency and Biood Stasis Stagnation), when compared with placebo and to explore the optimal dosage.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Jitongning tablet,3tablets,bid,treat 12 weeks
Other names: Jitongning tablet,3tablets
Jitongning tablet,2tablets,bid,treat 12 weeks Jitongning tablet placebo,1tablet,bid,treat 12 weeks
Other names: Jitongning tablet,2tablets,Jitongning tablet placebo,1tablet,
Jitongning tablet placebo,3tablets,bid,treat 12 weeks
Other names: Jitongning tablet placebo,3tablets
Time frame: 12 weeks
The percentage of subjects who achieved ASAS 20 response at 12th weeks
Time frame: 4 weeks,8weeks,12weeks
the score changes of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at each visit compared to baseline.
This instrument consists of six 10cm horizontal visual analog scales to measure severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness (both qualitative and quantitative). The final BASDAI score has a range of 0 to 10. The mean of which gives the BASDAI score (0-10). The severity of patient's symptoms from 0 (none) to 10 (most severe).
Time frame: 4 weeks,8weeks,12weeks
the score changes of Bath Ankylosing Spondylitis Functional Index (BASFI) at each visit compared to baseline.
This instrument consists of 8 specific questions regarding function in AS and 2 questions reflecting the patient's ability to cope with everyday life. Each question is answered on a 10 cm horizontal visual analog scale, the mean of which gives the BASFI score (0-10). The severity of patient's symptoms from 0 (none) to 10 (most severe).
Time frame: 4 weeks,8weeks,12weeks
the score changes of Spinal pain at each visit compared to baseline. Spinal pain was scored as the average of two VAS questions about total spinal pain and nocturnal spinal pain. The mean of which gives the spinal pain score (0-10). The severity of patient's symptoms from 0 (none) to 10 (most severe).
Time frame: 4 weeks,8weeks,12weeks
the score changes of PGA at each visit compared to baseline. Patient global assessment was measured using a set of visual analogue scales (VAS) on which patients rated the severity of their disease from 0 (none) to 10 (most severe).
Time frame: 4 weeks,8weeks,12weeks
the score changes of TCM syndrome scores at each visit compared to baseline. This instrument consists of three primary symptoms: spinal pain, spinal function limited, morning stiffness and six secondary symptoms: nocturnal back pain、stabbing pain、Local cold pain、aversion to cold,preference for heat、heel pain、weakness in the lower back and knees. Four levels to measure severity of primary symptoms(0、2、4、6)and secondary symptoms(0、1、2、3), respectively. Record the tongue and pulse conditions. The final score has a range of 0 to 100. The severity of patient's symptoms from 0 (none) to 100(most severe).The TCM syndrome effect calculated by nimodipine method. The effect of TCM syndrome from negative (worsen) to 100% (disappear).
Time frame: 4 weeks,8weeks,12weeks
the changes of CRP/hsCRP and ESR at each visit compared to baseline
Time frame: 12weeks
Exposure of ibuprofen sustained release capsules in test group and placebo at 12th weeks.
Exposure of ibuprofen sustained release capsules refers to the quantity of ibuprofen capsules patient actually took. The difference between the total dispensed quantity and the sum of recycling quantity and missing quantity gives the exposure of ibuprofen sustained release capsules. The exposure of ibuprofen sustained release capsules from 0 (none) to 372 (maximum).
Tasly Pharmaceutical Group Co., Ltd
Industry
A Randomized, Double-blind, Placebo-controled, Multi-center Phase II Clinical Trial for Evaluation of the Efficacy and Safety of Jitongning Tablet in Patients With Active Axial Spondyloarthritis(SpA)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04355923
Arthritis, Bone Diseases
Nice, France
View Trial DetailsNCT05345899
Arthritis, Autoimmune Diseases
Nice, Alpes Maritimes, France
View Trial DetailsNCT05424926
Arthritis, Arthritis, Psoriatic
Paris, IDF, France
View Trial DetailsNCT03458026
Arthritis, Behavior
Nice, France
View Trial Details